. "G44" . "262-268" . . "0260-437X" . "2"^^ . . "[55AE07EAE8B5]" . "Kassa, Ji\u0159\u00ED" . "Five oximes (K-27, K-33, K-48, BI-6 and methoxime) in comparison with pralidoxime: survival in rats exposed to the organophosphate paraoxon" . "475969" . . "Al-sultan, M. A. H." . "Five oximes (K-27, K-33, K-48, BI-6 and methoxime) in comparison with pralidoxime: survival in rats exposed to the organophosphate paraoxon"@en . "Petroianu, G. A." . . "RIV/60162694:G44__/06:00001456!RIV07-MO0-G44_____" . . "6"^^ . "P\u011Bt oxim\u016F (K-27, K-33, K-48, BI-6 a methoxim) ve srovn\u00E1n\u00ED s pralidoximem: p\u0159e\u017Eit\u00ED potkan\u016F exponovan\u00FDch organofosf\u00E1tem paraoxonem"@cs . "oximes; paraoxon; acetylcholinesterase; reactivator"@en . . "Journal of Applied Toxicology" . "Nurulain, S. M." . "Oximes are cholinesterase reactivators used in organophosphorus poisoning. Clinical experience with pralidoxime (PRX) and other oximes is disappointing and their routine use has been questioned. In addition it is known that not all oximes are equally effective against all existing organophosphorus compounds. There is a demand for broad-spectrum reactivators with a higher efficacy than PRX. Based on our previous in vitro work the protection conferred by the various new oximes against inhibition by paraoxon as quantified by the IC(50) shift (nM increase in the IC(50) of the inhibitor per microM oxime present) is: 0.3 (PRX), 0.4 (methoxime; MMC-4), 1 (K-33), 1.2 (BI-6), 1.5 (K-48) and 3.7 (K-27). The purpose of the study was to quantify in vivo the extent of oxime-conferred protection, using paraoxon (POX) as a cholinesterase inhibitor and to test whether in vitro efficacy translates to protection from mortality. There were seven groups of six rats in each cycle of the experiment. Group 1 (G1) received 1"@en . "3" . . "P\u011Bt oxim\u016F (K-27, K-33, K-48, BI-6 a methoxim) ve srovn\u00E1n\u00ED s pralidoximem: p\u0159e\u017Eit\u00ED potkan\u016F exponovan\u00FDch organofosf\u00E1tem paraoxonem"@cs . . "P(OBVLAJEP20032)" . "Five oximes (K-27, K-33, K-48, BI-6 and methoxime) in comparison with pralidoxime: survival in rats exposed to the organophosphate paraoxon" . . "Byly testov\u00E1ny nov\u00E9 reaktiv\u00E1tory AChE # K033, K027 a K048 pro svou schopnost reaktivovat erythrocyt\u00E1ln\u00ED AChE inhibovanou pesticidem paraoxonem pomoc\u00ED metody in vivo (potkan)."@cs . "RIV/60162694:G44__/06:00001456" . . . "Five oximes (K-27, K-33, K-48, BI-6 and methoxime) in comparison with pralidoxime: survival in rats exposed to the organophosphate paraoxon"@en . "26" . "Ku\u010Da, Kamil" . "7"^^ . "Negelkerke, N." . "Oximes are cholinesterase reactivators used in organophosphorus poisoning. Clinical experience with pralidoxime (PRX) and other oximes is disappointing and their routine use has been questioned. In addition it is known that not all oximes are equally effective against all existing organophosphorus compounds. There is a demand for broad-spectrum reactivators with a higher efficacy than PRX. Based on our previous in vitro work the protection conferred by the various new oximes against inhibition by paraoxon as quantified by the IC(50) shift (nM increase in the IC(50) of the inhibitor per microM oxime present) is: 0.3 (PRX), 0.4 (methoxime; MMC-4), 1 (K-33), 1.2 (BI-6), 1.5 (K-48) and 3.7 (K-27). The purpose of the study was to quantify in vivo the extent of oxime-conferred protection, using paraoxon (POX) as a cholinesterase inhibitor and to test whether in vitro efficacy translates to protection from mortality. There were seven groups of six rats in each cycle of the experiment. Group 1 (G1) received 1" . . . . "GB - Spojen\u00E9 kr\u00E1lovstv\u00ED Velk\u00E9 Brit\u00E1nie a Severn\u00EDho Irska" . . .